新股消息 | 京新药业(002020.SZ)递表港交所

Core Insights - Zhejiang Jingxin Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The company focuses on innovation-driven pharmaceutical development, targeting two core disease areas: central nervous system diseases and cardiovascular and cerebrovascular diseases [1] - Jingxin Pharmaceutical's business model combines the commercialization of existing products with the ongoing development of its product pipeline [1] Company Overview - Jingxin Pharmaceutical (002020.SZ) offers a diverse product portfolio that includes drugs (both generic and innovative), traditional Chinese medicine, biological agents, active pharmaceutical ingredients, and medical devices [1]